verapamil has been researched along with Sinusitis in 6 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Sinusitis: Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Verapamil is a calcium channel blocker that holds promise for the therapy of chronic rhinosinusitis (CRS) with and without nasal polyps." | 8.31 | Topical Administration of Verapamil in Poly(ethylene glycol)-Modified Liposomes for Enhanced Sinonasal Tissue Residence in Chronic Rhinosinusitis: ( Amiji, MM; Bleier, BS; D'Souza, A; Kutlehria, S; Taha, MS, 2023) |
| "Verapamil is a calcium channel blocker that holds promise for the therapy of chronic rhinosinusitis (CRS) with and without nasal polyps." | 4.31 | Topical Administration of Verapamil in Poly(ethylene glycol)-Modified Liposomes for Enhanced Sinonasal Tissue Residence in Chronic Rhinosinusitis: ( Amiji, MM; Bleier, BS; D'Souza, A; Kutlehria, S; Taha, MS, 2023) |
| "Verapamil is an L-type calcium channel blocker (CCB) that has been shown to have immunomodulatory properties in a variety of tissues." | 1.42 | Verapamil modulates interleukin-5 and interleukin-6 secretion in organotypic human sinonasal polyp explants. ( Bleier, BS; Han, X; Kocharyan, A; Singleton, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Workman, AD | 1 |
| Mueller, SK | 1 |
| McDonnell, K | 1 |
| Goldfarb, JW | 1 |
| Bleier, BS | 5 |
| Taha, MS | 2 |
| Kutlehria, S | 1 |
| D'Souza, A | 1 |
| Amiji, MM | 2 |
| Nocera, A | 2 |
| Workman, A | 1 |
| Kocharyan, A | 1 |
| Singleton, A | 1 |
| Han, X | 1 |
| Miyake, MM | 1 |
| Levesque, P | 1 |
| Guo, R | 1 |
| Finn, CA | 1 |
| Goldfarb, J | 1 |
| Gray, S | 1 |
| Holbrook, E | 1 |
| Busaba, N | 1 |
| Dolci, JEL | 1 |
| Steenbergen, JA | 1 |
| Stauffer, VL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps[NCT03102190] | Phase 1 | 6 participants (Actual) | Interventional | 2017-06-05 | Terminated (stopped due to Phase II funding not available) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Dose Limiting Toxicity will be defined as a development of 2nd or 3rd degree heart block as measured by an EKG. (Phase Ib primary outcome) (NCT03102190)
Timeframe: 1-8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase Ib | 0 |
1 trial available for verapamil and Sinusitis
| Article | Year |
|---|---|
Phase I safety and tolerability study of topical verapamil HCl in chronic rhinosinusitis with nasal polyps.
Topics: Chronic Disease; Humans; Nasal Polyps; Rhinitis; Sinusitis; Verapamil | 2022 |
5 other studies available for verapamil and Sinusitis
| Article | Year |
|---|---|
Topical Administration of Verapamil in Poly(ethylene glycol)-Modified Liposomes for Enhanced Sinonasal Tissue Residence in Chronic Rhinosinusitis:
Topics: Administration, Intranasal; Administration, Topical; Animals; Liposomes; Mice; Mice, Inbred C57BL; P | 2023 |
P-glycoprotein inhibition with verapamil overcomes mometasone resistance in Chronic Sinusitis with Nasal Polyps.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2021 |
Verapamil modulates interleukin-5 and interleukin-6 secretion in organotypic human sinonasal polyp explants.
Topics: Calcium Channel Blockers; Cells, Cultured; Chronic Disease; Dexamethasone; Enterotoxins; Humans; Imm | 2015 |
Double-blind placebo-controlled randomized clinical trial of verapamil for chronic rhinosinusitis with nasal polyps.
Topics: Case-Control Studies; Chronic Disease; Humans; Immunologic Factors; Nasal Polyps; Rhinitis; Sinusiti | 2017 |
Potential macrolide interaction with verapamil.
Topics: Aged; Anti-Bacterial Agents; Cardiomyopathy, Hypertrophic; Contraindications; Drug Interactions; Fem | 1998 |